Ware J. Anthony 4/A

What Happened
Ware J. Anthony, a director of First Tracks Biotherapeutics, was awarded equity on May 12, 2026: 7,000 stock options and 2,500 restricted stock units (RSUs). The filing reports these as awards (derivative transactions) with an acquisition price listed as $0.00. The Form 4 was amended on June 12, 2026 to correct the award amounts (original Form 4 filed May 14, 2026).

Key Details

• Transaction date: May 12, 2026. Initial Form 4 filed May 14, 2026; amended on June 12, 2026 to correct amounts.
• Grants: 7,000 stock options and 2,500 RSUs; acquisition price shown as $0.00 (typical for grant reporting).
• RSU terms (Footnote F1–F2): Each RSU represents a contingent right to 1 share upon settlement for no consideration; RSUs vest 100% on the date of the issuer's 2027 annual meeting, subject to continued service.
• Option vesting (Footnote F3): The options vest 1/12 of the total shares monthly beginning June 12, 2026 until fully vested, subject to continued service.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Filing status: This is an amended Form 4 correcting the originally reported award amounts; the original filing was within the typical 2-business-day window after the May 12 transaction.

Context
These are grant awards, not open-market purchases or sales. Grants are common as compensation/retention and do not, by themselves, indicate the director bought or sold shares. RSUs are settled for shares (no additional cash) when they vest; options will vest monthly per the schedule — whether the options have a strike price or will be exercised/sold later is not detailed in the provided filing. The amendment simply corrects the counts to 7,000 options and 2,500 RSUs.